Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKesson
McKinsey
AstraZeneca
Johnson and Johnson

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Etelcalcetide - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for etelcalcetide and what is the scope of freedom to operate?

Etelcalcetide is the generic ingredient in one branded drug marketed by Kai Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etelcalcetide has eighty-seven patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for etelcalcetide
International Patents:87
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 11
Clinical Trials: 7
Drug Prices: Drug price trends for etelcalcetide
DailyMed Link:etelcalcetide at DailyMed
Drug Prices for etelcalcetide

See drug prices for etelcalcetide

Recent Clinical Trials for etelcalcetide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Prim. Priv. Doz. Dr. Daniel CejkaPhase 2
AmgenPhase 2
Thomas Nickolas, MD MSPhase 2

See all etelcalcetide clinical trials

Pharmacology for etelcalcetide
Synonyms for etelcalcetide
1262780-97-1
60ME133FJB
AMG 416
AMG-416
CHEBI:134700
CHEMBL3545184
D-Argininamide, N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-, disulfide with L-cysteine
D10676
DB12865
DTXSID70155132
Etelcalcetide (USAN/INN)
Etelcalcetide [USAN:INN]
Etelcalcetide Hydrochloride(AMG-416)
J3.559.823E
KAI 4169
KAI-4169
Parsabiv
UNII-60ME133FJB
Velcalcetide

US Patents and Regulatory Information for etelcalcetide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-002 Feb 7, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-003 Feb 7, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-002 Feb 7, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-003 Feb 7, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-001 Feb 7, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for etelcalcetide

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2459208 1790012-7 Sweden   Start Trial PRODUCT NAME: ETELCALCETIDE, OR SALT THEREOF, INCLUDING ETELCALCETIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1142/001-012 20161115
2459208 2017021 Norway   Start Trial PRODUCT NAME: ETELKALSETID, ELLER ET SALT DERAV, INKLUDERT ETELKALSETIDHYDROKLORID; NAT. REG. NO/DATE: EU/1/16/1142 20161122; FIRST REG. NO/DATE: EU/1/16/1142/001-012 20161115
2459208 PA2017007 Lithuania   Start Trial PRODUCT NAME: ETELKALCETIDAS ARBA JO DRUSKA, ISKAITANT ETELKALCETIDO HIDROCHLORIDA; REGISTRATION NO/DATE: EU/1/16/1142 20161111
2459208 C20170006 00208 Estonia   Start Trial PRODUCT NAME: ETELKALTSETIID;REG NO/DATE: EU/1/16/1142 15.11.2016
2459208 LUC00008 Luxembourg   Start Trial PRODUCT NAME: ETELCALCETIDE, OU UN SEL EQUIVALENT, Y COMPRIS LE CHLORHYDRATE D'ETELCALCETIDE (PARSABIV); AUTHORISATION NUMBER AND DATE: EU/1/16/1142 20161115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Express Scripts
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.